TRCT
EFTR

Tower Research Capital (TRC)’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Tower Research Capital (TRC)’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,805
Closed -$2.84K – 6147
2024
Q2 		$2.84K Buy
9,805
+8,271
+539% +$19.6K ﹤0.01% 4961
2024
Q1 		$22.1K Buy
1,534
+1,487
+3,164% +$17.8K ﹤0.01% 2912
2023
Q4 		$545 Sell
47
-446
-90% -$5.98K ﹤0.01% 5543
2023
Q3 		$7.4K Buy
493
+78
+19% +$1.35K ﹤0.01% 4471
2023
Q2 		$8.62K Buy
415
+2
+0.5% +$34 ﹤0.01% 4403
2023
Q1 		$4K Sell
413
-496
-55% -$6.02K ﹤0.01% 5132
2022
Q4 		$10K Buy
909
+253
+39% +$3.21K ﹤0.01% 4107
2022
Q3 		$9K Buy
656
+357
+119% +$7K ﹤0.01% 4720
2022
Q2 		$11K Buy
299
+277
+1,259% +$16.8K ﹤0.01% 4400
2022
Q1 		$2K Sell
22
-7
-24% -$930 ﹤0.01% 5636
2021
Q4 		$7K Sell
29
-245
-89% -$56.9K ﹤0.01% 4961
2021
Q3 		$97K Buy
+274
New +$88.3K ﹤0.01% 2429

Other funds holding EFTR

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Tower Research Capital (TRC)'s EFTR Position: Q3 2024 in Review

Tower Research Capital (TRC) sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2024, closing a stake of 9,805 shares — an estimated $2.84K sold.

Tower Research Capital (TRC) first reported a position in EFTR in Q3 2021 and held it in 12 quarters. The position peaked at $97K in Q3 2021. 3 funds tracked by Wall St. Rank hold EFTR as of Q3 2024.

  • Tower Research Capital (TRC) reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 9,805 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $2.84K.
  • Tower Research Capital (TRC) first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q3 2021 and held it in 12 quarters.
  • Tower Research Capital (TRC)'s eFFECTOR Therapeutics, Inc. Common Stock position peaked at $97K in Q3 2021.
  • 3 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2024, filed 14 Nov 2024.